Literature DB >> 22226862

Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signaling.

Evandro R Winkelmann1, Douglas G Widman, Jingya Xia, Tomohiro Ishikawa, Mindy Miller-Kittrell, Michelle H Nelson, Nigel Bourne, Frank Scholle, Peter W Mason, Gregg N Milligan.   

Abstract

Type I interferons (IFNs) are critical for controlling pathogenic virus infections and can enhance immune responses. Hence their impact on the effectiveness of live-attenuated vaccines involves a balance between limiting viral antigen expression and enhancing the development of adaptive immune responses. We examined the influence of type I IFNs on these parameters following immunization with RepliVAX WN, a single-cycle flavivirus vaccine (SCFV) against West Nile virus (WNV) disease. RepliVAX WN-immunized mice produced IFN-α and displayed increased IFN-stimulated gene transcription in draining lymph nodes (LN). SCFV gene expression was over 100 fold-higher on days 1-3 post-infection in type I IFN receptor knockout mice (IFNAR(-/-)) compared to wild-type (wt) mice indicating a profound IFN-mediated suppression of SCFV gene expression in the wt animals. IFNAR(-/-) mice produced nearly equivalent levels of WNV-specific serum IgG and WNV-specific CD4(+) T cell responses compared to wt mice. However, significantly higher numbers of WNV-specific CD8(+) T cells were produced by IFNAR(-/-) mice and a significantly greater percentage of these T cells from IFNAR(-/-) mice produced only IFN-γ following antigen-specific re-stimulation. This altered cytokine expression was not associated with increased antigen load suggesting the loss of type I IFN receptor signaling was responsible for the altered quality of the CD8(+) effector T cell response. Together, these results indicate that although type I IFN is not essential for the intrinsic adjuvanting of RepliVAX WN, it plays a role in shaping the cytokine secretion profiles of CD8(+) effector T cells elicited by this SCFV.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22226862      PMCID: PMC3274573          DOI: 10.1016/j.vaccine.2011.12.103

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  45 in total

1.  Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.

Authors:  A Le Bon; G Schiavoni; G D'Agostino; I Gresser; F Belardelli; D F Tough
Journal:  Immunity       Date:  2001-04       Impact factor: 31.745

2.  West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection.

Authors:  James D Brien; Jennifer L Uhrlaub; Janko Nikolich-Zugich
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

Review 3.  Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity.

Authors:  Michaela Prchal; Andreas Pilz; Olivia Simma; Karen Lingnau; Alexander von Gabain; Birgit Strobl; Mathias Müller; Thomas Decker
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

4.  Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine.

Authors:  Michelle H Nelson; Evandro Winkelmann; Yinghong Ma; Jingya Xia; Peter W Mason; Nigel Bourne; Gregg N Milligan
Journal:  Vaccine       Date:  2010-11-04       Impact factor: 3.641

5.  Type I interferon inhibits interleukin-1 production and inflammasome activation.

Authors:  Greta Guarda; Marion Braun; Francesco Staehli; Aubry Tardivel; Chantal Mattmann; Irmgard Förster; Matthias Farlik; Thomas Decker; Renaud A Du Pasquier; Pedro Romero; Jürg Tschopp
Journal:  Immunity       Date:  2011-02-25       Impact factor: 31.745

6.  Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection.

Authors:  Douglas G Widman; Tomohiro Ishikawa; Luis D Giavedoni; Vida L Hodara; Melissa de la Garza; Jessica A Montalbo; Amelia P Travassos Da Rosa; Robert B Tesh; Jean L Patterson; Ricardo Carrion; Nigel Bourne; Peter W Mason
Journal:  Am J Trop Med Hyg       Date:  2010-06       Impact factor: 2.345

7.  RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters.

Authors:  Douglas G Widman; Tomohiro Ishikawa; Evandro R Winkelmann; Ernesto Infante; Nigel Bourne; Peter W Mason
Journal:  Vaccine       Date:  2009-07-25       Impact factor: 3.641

8.  Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys.

Authors:  Michael M Lieberman; Vivek R Nerurkar; Haiyan Luo; Bruce Cropp; Ricardo Carrion; Melissa de la Garza; Beth-Ann Coller; David Clements; Steven Ogata; Teri Wong; Tim Martyak; Carolyn Weeks-Levy
Journal:  Clin Vaccine Immunol       Date:  2009-07-29

9.  MyD88 and Type I interferon receptor-mediated chemokine induction and monocyte recruitment during Listeria monocytogenes infection.

Authors:  Ting Jia; Ingrid Leiner; Guillaume Dorothee; Katharina Brandl; Eric G Pamer
Journal:  J Immunol       Date:  2009-06-24       Impact factor: 5.422

10.  West Nile virus genome amplification requires the functional activities of the proteasome.

Authors:  Felicia Gilfoy; Rafik Fayzulin; Peter W Mason
Journal:  Virology       Date:  2008-12-19       Impact factor: 3.616

View more
  8 in total

Review 1.  Cell-intrinsic innate immune control of West Nile virus infection.

Authors:  Michael S Diamond; Michael Gale
Journal:  Trends Immunol       Date:  2012-06-20       Impact factor: 16.687

2.  Subcapsular sinus macrophages limit dissemination of West Nile virus particles after inoculation but are not essential for the development of West Nile virus-specific T cell responses.

Authors:  Evandro R Winkelmann; Douglas G Widman; Jingya Xia; Alison J Johnson; Nico van Rooijen; Peter W Mason; Nigel Bourne; Gregg N Milligan
Journal:  Virology       Date:  2014-01-10       Impact factor: 3.616

3.  Blocking Virus Replication during Acute Murine Cytomegalovirus Infection Paradoxically Prolongs Antigen Presentation and Increases the CD8+ T Cell Response by Preventing Type I IFN-Dependent Depletion of Dendritic Cells.

Authors:  Christopher P Loo; Christopher M Snyder; Ann B Hill
Journal:  J Immunol       Date:  2016-11-21       Impact factor: 5.422

4.  TLR3- and MyD88-dependent signaling differentially influences the development of West Nile virus-specific B cell responses in mice following immunization with RepliVAX WN, a single-cycle flavivirus vaccine candidate.

Authors:  Jingya Xia; Evandro R Winkelmann; Summer R Gorder; Peter W Mason; Gregg N Milligan
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

Review 5.  Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor.

Authors:  Alejandro Marín-Lopez; Eva Calvo-Pinilla; Sandra Moreno; Sergio Utrilla-Trigo; Aitor Nogales; Alejandro Brun; Erol Fikrig; Javier Ortego
Journal:  Viruses       Date:  2019-01-08       Impact factor: 5.048

6.  TIM-1 serves as a receptor for Ebola virus in vivo, enhancing viremia and pathogenesis.

Authors:  Bethany Brunton; Kai Rogers; Elisabeth K Phillips; Rachel B Brouillette; Ruayda Bouls; Noah S Butler; Wendy Maury
Journal:  PLoS Negl Trop Dis       Date:  2019-06-26

7.  Source and Purity of Dengue-Viral Preparations Impact Requirement for Enhancing Antibody to Induce Elevated IL-1β Secretion: A Primary Human Monocyte Model.

Authors:  Justin B Callaway; Scott A Smith; Douglas G Widman; Karen P McKinnon; Frank Scholle; Gregory D Sempowski; Dirk P Dittmer; James E Crowe; Aravinda M de Silva; Jenny P-Y Ting
Journal:  PLoS One       Date:  2015-08-24       Impact factor: 3.240

8.  Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge.

Authors:  Marko Zivcec; David Safronetz; Dana P Scott; Shelly Robertson; Heinz Feldmann
Journal:  PLoS Negl Trop Dis       Date:  2018-07-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.